Mira Pharmaceuticals (MIRA) Cash from Financing Activities (2022 - 2025)

Mira Pharmaceuticals has reported Cash from Financing Activities for 4 years, with the latest figure at $4.8 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 881.03% year-over-year to $4.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.2 million (up 115.66% YoY) and the FY2025 annual result came in at $8.2 million, up 115.66% from the prior year.
• Cash from Financing Activities grew to $4.8 million in Q4 2025 per MIRA's latest filing, from $3.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $7.6 million in Q3 2023 and troughed at -$230749.0 in Q4 2023.
• A 4-year average of $1.6 million and a median of $680354.5 in 2022 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 1024.27% in 2023, down 120.26% in 2023.
• Over 4 years, Cash from Financing Activities stood at $1.1 million in 2022, then slumped by 120.26% to -$230749.0 in 2023, then soared by 313.83% to $493401.0 in 2024, then surged by 881.03% to $4.8 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $4.8 million, $3.0 million, and $323841.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.